Recently, the U.S. Food and Drug Administration (FDA) approved a new Deep Brain Stimulation (DBS) System for treating the symptoms of Parkinson's disease (PD). This system works by stimulating a targeted region of the brain through implanted leads which are powered by a device called an implantable pulse generator (IPG). PD is a long-term degenerative condition of the central nervous system that mainly affects the motor system. PD have known to affect about 10 million people worldwide.
The Deep brain stimulation (DBS) generally helps to control movement-related symptoms of Parkinson’ such as tremor, bradykinesia, and rigidity. Clinical study The approval was mainly based on the first multicenter, prospective, double-blind, randomized (INTREPID) study of DBS for PD. This study evaluated the safety and effectiveness of the system in 292 patients at 23 sites. The primary endpoint was…
